The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma

被引:95
作者
Nahas, Z
Goldenberg, D
Fakhry, C
Ewertz, M
Zeiger, M
Ladenson, PW
Wahl, R
Tufano, RP
机构
[1] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA
[2] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA
[3] Johns Hopkins Sch Med, Div Endocrinol, Dept Med, Baltimore, MD USA
[4] Johns Hopkins Sch Med, Div Nucl Med, Dept Radiol, Baltimore, MD USA
关键词
positron emission tomography/computed tomography; papillary thyroid carcinoma; positron emission tomography with radiolabeled glucose analogue 2-flouro-2-deoxy-D-glucose;
D O I
10.1097/01.mlg.0000154725.00787.00
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis. The aim of the study was to evaluate the role of combined positron emission tomography/computed tomography (PET/CT) fusion imaging in the detection and management of recurrent papillary thyroid cancer. Study Design. A retrospective analysis of 33 patients with suspected recurrent papillary thyroid carcinoma who had undergone PET/CT was performed. PET/CT was compared with standard imaging techniques in each patient to determine whether PET/CT contributed to the therapeutic management plan. Histopathological findings were correlated to PET/CT in patients who underwent surgery. Methods: The senior author reviewed the charts of 33 patients with recurrent papillary thyroid carcinoma to determine the impact PET/CT had on management. PET/CT was compared with conventional imaging results. In surgical patients, PET/CT was compared with histopathological findings to determine its sensitivity, specificity, accuracy, positive predictive value, and negative predictive value. Results. In 67% of the cases (22 of 33), PET/CT supplied additional information that altered or confirmed the management plan. Twenty of 33 patients underwent surgery with 36 sites assessed by histopathological analysis. PET/CT correlated with histopathological findings in 25 of 36 distinct anatomical sites, with an accuracy of 70%. The sensitivity of PET/CT in identifying recurrence was found to be 66%, with a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 27%. Conclusion: Combined PET/CT fusion scanning was most useful in the detection and management of recurrent papillary thyroid cancer in patients who had average thyroglobulin levels greater than 10 ng/mL and when the tumor no longer concentrated radioactive iodine. In 100% of the cases in which PET/CT localized a region suspicious for malignancy, histopathological analysis confirmed the results. When PET/CT is positive, it is a powerful tool for predicting exact locations of recurrent papillary thyroid cancer, thus making it a reliable guide for surgical planning. PET/CT is a supplement to conventional imaging and fine-needle aspiration in the workup of recurrent papillary thyroid cancer. A negative finding on PET/CT is not sufficiently reliable to preclude further investigation and treatment.
引用
收藏
页码:237 / 243
页数:7
相关论文
共 13 条
[1]   Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans [J].
Altenvoerde, G ;
Lerch, H ;
Kuwert, T ;
Matheja, P ;
Schafers, M ;
Schober, O .
LANGENBECKS ARCHIVES OF SURGERY, 1998, 383 (02) :160-163
[2]  
Beyer T, 2000, J NUCL MED, V41, P1369
[3]  
Chung JK, 1999, J NUCL MED, V40, P986
[4]   MANAGEMENT OF PATIENTS WITH DIFFERENTIATED THYROID-CANCER WHO HAVE POSITIVE SERUM THYROGLOBULIN LEVELS AND NEGATIVE RADIOIODINE SCANS [J].
CLARK, OH ;
HOELTING, T .
THYROID, 1994, 4 (04) :501-505
[5]   Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer [J].
Dietlein, M ;
Scheidhauer, K ;
Voth, E ;
Theissen, P ;
Schicha, H .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (11) :1342-1348
[6]   Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer [J].
Feine, U .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 138 (05) :492-496
[7]   Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma [J].
Frasoldati, A ;
Pesenti, M ;
Gallo, M ;
Caroggio, A ;
Salvo, D ;
Valcavi, R .
CANCER, 2003, 97 (01) :90-96
[8]   Preoperative diagnostic value [18F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma [J].
Frilling, A ;
Tecklenborg, K ;
Görges, R ;
Weber, F ;
Clausen, M ;
Broelsch, EC .
ANNALS OF SURGERY, 2001, 234 (06) :804-811
[9]   Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer [J].
Grunwald, F ;
Schomburg, A ;
Bender, H ;
Klemm, E ;
Menzel, C ;
Bultmann, T ;
Palmedo, H ;
Ruhlmann, J ;
Kozak, B ;
Biersack, HJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (03) :312-319
[10]   An overview of the management of papillary and follicular thyroid carcinoma [J].
Mazzaferri, EL .
THYROID, 1999, 9 (05) :421-427